Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine® technology IMNN-101 induced 2- to 4-fold increase in neutralizing ...

Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine® ...

A live webcast of the presentation can be accessed on the “Events & Presentations” page in the Investor section of Korro’s website at www.korrobio.com. Following the presentation, a replay of the ...

Currently, there are limited methods to protect cancer patients from radiation damage. A few drugs can help reduce this ...

Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence ...

When people undergo radiotherapy for cancer, it's not just the tumor that suffers. The radiation causes DNA breaks in healthy ...

About 60% of all cancer patients in the United States receive radiation therapy as part of their treatment. However, this ...

In an international collaboration, researchers have made an important breakthrough in the therapeutic delivery of microRNAs ...

India’s CRDMO market, currently holding 2-3% of the global share, has the potential to reach $22-25 billion by 2035, says a ...

India's CRDMO sector is set to reach USD 22-25 billion by 2035, driven by cost advantages and rapid project startups, according to a BCG and IPSO report. India is emerging as a preferred outsourcing ...

Researchers from Cleveland Clinic's Genome Center have outlined the pathway human herpes simplex virus-1 (HSV1) can use to ...

Company expands multiomics portfolio with new roadmap technologies spanning genomics, spatial, single cell, CRISPR, and ...